06/15/2021 ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions Icon check
06/10/2021 Number of shares and voting rights of ADOCIA as of May 31st, 2021 Icon check
06/08/2021 ADOCIA confirms its eligibility for the PEA–PME Icon check
06/02/2021 ADO09, a co-formulation of pramlintide and insulin A21G improves postprandial glucose (PPG) versus insulin Aspart  in type 1 diabetes, Dr.  Grégory Meiffren, June 2, 2021, ATTD, Virtual event.
06/02/2021 ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021 Icon check
06/01/2021 ADOCIA reinforces its board of directors with the appointment of three new independent members. Icon check
05/26/2021 ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps Icon check
05/17/2021 Number of shares and voting rights of ADOCIA as of April 30, 2021 Icon check
05/11/2021 ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021 Icon check
04/23/2021 ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab., 2021;23(4):961-970. Icon check
04/21/2021 ADOCIA Announces the Release of its Universal Registration Document for the Year 2020 Icon check
04/21/2021 ADOCIA Announces First Quarter 2021 Financial Results Icon check
04/19/2021 ADOCIA: Number of shares and voting rights of ADOCIA as of March 31st, 2021 Icon check
03/18/2021 ADOCIA Announces Financial Results 2020 And Provides Corporate Update. Icon check
03/17/2021 Number of shares and voting rights of ADOCIA as of February 28th, 2021 Icon check
03/10/2021 Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes Icon check
02/16/2021 Number of shares and voting rights of ADOCIA as of January 31, 2021 Icon check
01/25/2021 Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao Icon check
01/20/2021 Number of shares and voting rights of ADOCIA as of December 31, 2020 Icon check
01/18/2021 Adocia Announces half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
01/11/2021 Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes Icon check
12/21/2020 Adocia announces its financial calendar for 2021 Icon check
12/07/2020 Number of shares and voting rights of ADOCIA as of November 30, 2020 Icon check
11/06/2020 Number of shares and voting rights of ADOCIA as of October 31, 2020 Icon check
10/20/2020 Adocia Announces Third Quarter 2020 Financial Results Icon check
10/09/2020 Number of shares and voting rights of ADOCIA as of September 30, 2020 Icon check
09/22/2020 Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020 Icon check
09/15/2020 Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes. Icon check
09/10/2020 ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr.  Grégory Meiffren, September 10, 2020, Société Francophone du Diabète, Virtual Event.
09/08/2020 Number of shares and voting rights of ADOCIA as of August 31, 2020 Icon check
09/07/2020 September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event) Icon check
09/05/2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
09/03/2020 September 10th: Adocia Oral Presentation at the Annual Congress of the Société Francophone du Diabète (SFD). Icon check
08/25/2020 Number of shares and voting rights of ADOCIA as of July 31, 2020 Icon check
08/18/2020 Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019. Icon check
07/30/2020 Adocia initiates BioChaperone® Lispro comparative study to validate THDB insulin lispro for Phase 3 BC Lispro trials in Europe and U.S Icon check
07/20/2020 Adocia Announces First Half 2020 Financial Results Icon check
07/06/2020 Number of shares and voting rights of ADOCIA as of June 30, 2020 Icon check
06/16/2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
06/16/2020 ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience. Icon check
06/16/2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
06/08/2020 Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience Icon check
06/05/2020 Number of shares and voting rights of ADOCIA as of May 31, 2020 Icon check
06/03/2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
05/11/2020 Number of shares and voting rights of ADOCIA as of April 30, 2020 Icon check
04/23/2020 Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes Icon check
04/23/2020 Adocia announces the release of its Universal Reference Document for the year 2019 Icon check
04/20/2020 Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon Icon check
04/14/2020 Adocia announces first quarter 2020 financial results and update on the impact of COVID-19 Icon check
04/09/2020 Number of shares and voting rights of ADOCIA as of March 31, 2020 Icon check
03/12/2020 Adocia Announces Full Year 2019 Financial Results Icon check
03/05/2020 Number of shares and voting rights of ADOCIA as of February 28, 2020 Icon check
02/21/2020 “BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany) Icon check
01/07/2020 Number of shares and voting rights of ADOCIA as of December 31, 2019 Icon check
12/17/2019 Adocia announces its financial calendar for 2020 Icon check
12/11/2019 Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners Icon check
12/06/2019 Number of shares and voting rights of ADOCIA as of November 30, 2019 Icon check
11/07/2019 Number of shares and voting rights of ADOCIA as of October 31st, 2019 Icon check
10/22/2019 Adocia Announces Third Quarter 2019 Financial Results Icon check
10/14/2019 Adocia obtains additional financial resources to accelerate its growth Icon check
Join our mailing list. Subscribe